SeekingAlpha · Aug 12, 2026
Humacyte, Inc. (HUMA) Q2 2026 Earnings Call Transcript
Humacyte, Inc. (HUMA) Q2 2026 Earnings Call August 12, 2026 8:00 AM EDTCompany ParticipantsLaura Niklason - Founder, President, CEO & DirectorJim...
HU
NASDAQ · HUMAW
Humacyte, Inc.
Healthcare · Biotechnology
$0.01
Down-$0.00 (-6.67%)
Updated Aug 15, 2026, 5:33 PM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 161.53M
- P/E ratio
- -10.7
- Dividend yield
- 0.00%
- 52-week range
- $0.00 – $0.13
- Volume
- 10.21K
- Avg. volume
- 20.94K
Price performance
HUMAW price history
1M range · 20 trading sessions · Daily adjusted prices
HUMAW closed at $0.01 after 20 trading sessions, down 23.91% for the selected period.
- Last close
- $0.01
- Period change
- -23.91%
- Period low
- $0.01
- Period high
- $0.01
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $0.0053 | $0.007 | $0.0053 | $0.007 | 10.21K |
| Aug 13, 2026 | $0.0062 | $0.0075 | $0.0062 | $0.0075 | 13.13K |
| Aug 12, 2026 | $0.009 | $0.009 | $0.006 | $0.006 | 54.57K |
| Aug 11, 2026 | $0.009 | $0.009 | $0.009 | $0.009 | 4.58K |
| Aug 10, 2026 | $0.007 | $0.009 | $0.007 | $0.0089 | 2.71K |
| Aug 7, 2026 | $0.009 | $0.009 | $0.0071 | $0.008 | 1.36K |
| Aug 6, 2026 | $0.007 | $0.009 | $0.007 | $0.009 | 1.21K |
| Aug 5, 2026 | $0.009 | $0.009 | $0.007 | $0.007 | 6.37K |
| Aug 4, 2026 | $0.008 | $0.008 | $0.0069 | $0.0069 | 22.82K |
| Aug 3, 2026 | $0.008 | $0.0099 | $0.008 | $0.0082 | 18.86K |
| Jul 31, 2026 | $0.008 | $0.01 | $0.008 | $0.01 | 514.45K |
| Jul 30, 2026 | $0.009 | $0.009 | $0.009 | $0.009 | 24.42K |
| Jul 29, 2026 | $0.009 | $0.0091 | $0.009 | $0.0091 | 1.81K |
| Jul 28, 2026 | $0.0092 | $0.0092 | $0.008 | $0.009 | 63.82K |
| Jul 27, 2026 | $0.0091 | $0.01 | $0.0091 | $0.01 | 707 |
| Jul 24, 2026 | $0.0091 | $0.01 | $0.0091 | $0.01 | 11.66K |
| Jul 22, 2026 | $0.0099 | $0.0099 | $0.0091 | $0.0099 | 1.45K |
| Jul 21, 2026 | $0.0091 | $0.01 | $0.0091 | $0.01 | 2.94K |
| Jul 20, 2026 | $0.0099 | $0.0099 | $0.0098 | $0.0098 | 206 |
| Jul 17, 2026 | $0.0092 | $0.0092 | $0.0092 | $0.0092 | 2.04K |
Latest HUMAW news
The latest Smart Investors Daily articles mentioning HUMAW.
Stock researchCompany · Overview
HUMAW research
Overview
Company profile and research snapshot.
Company profile
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Yahoo · Aug 7, 2026
Humacyte To Announce 2026 Second Quarter Financial Results and Provide Business Update on August 12, 2026
DURHAM, N.C., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company will release its financial results for the three months and six months ended June 30, 2026, on Wednesday, August 12, 2026. Management will host a webcast and conference call at 8:00 a.m. Eastern Time to provide a corporate and financial update. TitleHum
Yahoo · Aug 5, 2026
Humacyte, Inc. (HUMA) Rises As Market Takes a Dip: Key Facts
Humacyte, Inc. (HUMA) concluded the recent trading session at $0.73, signifying a +2.33% move from its prior day's close.
SeekingAlpha · Jun 15, 2026
Humacyte, Inc. (HUMA) Discusses V012 Study Top-Line Results for Engineered Vessel in Dialysis Access Transcript
Humacyte, Inc. (HUMA) Discusses V012 Study Top-Line Results for Engineered Vessel in Dialysis Access June 15, 2026 5:00 PM EDTCompany ParticipantsLaura...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
